Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials

Poulsen, 2015, Evolving paradigms in the treatment of opioid-induced bowel dysfunction, Therap Adv Gastroenterol, 8, 360, 10.1177/1756283X15589526 Morlion, 2015, Quality of life and health-care resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone, Clin Drug Investig, 35, 1, 10.1007/s40261-014-0254-6 Lazzari, 2015, Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naive cancer patients: a propensity analysis, Drug Des Devel Ther, 9, 5863, 10.2147/DDDT.S92998 Camilleri, 2011, Opioid-induced constipation: challenges and therapeutic opportunities, Am J Gastroenterol, 106, 835, 10.1038/ajg.2011.30 Bruner, 2015, Clinical utility of naloxegol in the treatment of opioid-induced constipation, J Pain Res, 8, 289 Bell, 2009, The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1), Pain Med, 10, 35, 10.1111/j.1526-4637.2008.00495.x Camilleri, 2014, Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation, Neurogastroenterol Motil, 26, 1386, 10.1111/nmo.12417 Kalso, 2004, Opioids in chronic non-cancer pain: systematic review of efficacy and safety, Pain, 112, 372, 10.1016/j.pain.2004.09.019 Moore, 2005, Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids, Arthritis Res Ther, 7, R1046, 10.1186/ar1782 2014 2015 Chey, 2014, Naloxegol for opioid-induced constipation in patients with non-cancer pain, N Engl J Med, 370, 2387, 10.1056/NEJMoa1310246 Michna, 2011, Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study, J Pain, 12, 554, 10.1016/j.jpain.2010.11.008 Thomas, 2008, Methylnaltrexone for opioid-induced constipation in advanced illness, N Engl J Med, 358, 2332, 10.1056/NEJMoa0707377 Kanemasa, 2015, Effects of naldemedine: a peripherally acting mu-opioid receptor antagonist in rat models of opioid-induced constipation, Am J Gastroenterol, 110, S578, 10.14309/00000434-201510001-01322 Fukumura, 2016, Phase 1 randomised, double-blind, placebo-controlled studies of the safety, tolerability and pharmacokinetics of naldemedine in healthy volunteers, Gastroenterology, 150, S537, 10.1016/S0016-5085(16)31849-2 Webster, 2017, A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain, Pain Med Coyne, 2015, Opioid-induced constipation among patients with chronic non-cancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time, Pain Med, 16, 1551, 10.1111/pme.12724 Webster, 2014, Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation, Aliment Pharmacol Ther, 40, 771, 10.1111/apt.12899